Elsevier

The Lancet

Volume 343, Issue 8888, 1 January 1994, Pages 25-26
The Lancet

Lesional expression of interferon-γ in atopic eczema

https://doi.org/10.1016/S0140-6736(94)90879-6Get rights and content

Abstract

Atopic eczema is thought to be caused by skin-infiltrating CD4 T cells of the Th1-like and/or Th2-like subtype. We assessed expression of the Th1-like cytokine, interferon-γ, and the Th2-like cytokine, interleukin-4, in lesional atopic skin. Compared with that in normal skin, interferon-γ and interleukin-4 mRNA expression were increased in eczematous skin lesions in 13 and 4 of 15 patients, respectively. After successful therapy of atopic dermatitis, the increased interferon-γ mRNA expression but not the increased interleukin-4 mRNA expression was significantly downregulated. These data indicate that in-situ expression of interferon-γ is linked to the clinical course of atopic dermatitis.

References (10)

There are more references available in the full text version of this article.

Cited by (392)

  • T-Cell‒Mediated Autoimmunity: Mechanisms and Future Directions

    2022, Journal of Investigative Dermatology
    Citation Excerpt :

    Examples of diseases belonging to pattern 2 are atopic dermatitis (AD) and other types of eczema; chronic urticaria; and autoimmune bullous diseases such as BP, epidermolysis bullosa acquisita, or herpetiform dermatitis (Eyerich and Eyerich, 2018). In addition to the type 2 immune signature that is present in virtually all forms of AD, type 1 cytokines might be observed in chronic lesions (Grewe et al., 1994; Werfel et al., 1996) and in Th17 signatures preferentially in children (Esaki et al., 2016) and in people with Asian descent (Noda et al., 2015), respectively. As shown before in BP and other autoimmune diseases (Döpp et al., 2000; Sanjuan et al., 2016), IgE-mediated autoimmunity seems to play a key role in the prototype pattern 2 disease AD (Cipriani et al., 2014; Roesner and Werfel, 2019; Tang et al., 2012).

  • Innate Immune Regulation of Dermatitis

    2021, Immunology and Allergy Clinics of North America
  • Utilizing UVA-1 Phototherapy

    2020, Dermatologic Clinics
  • Nanomaterials as photothermal therapeutic agents

    2019, Progress in Materials Science
View all citing articles on Scopus
View full text